Key result
An analysis of the EINSTEIN trials assessed the length of initial hospitalisation for patients with DVT or PE treated with rivaroxaban, though no quantitative results were reported in the abstract.
Why the study?
Does oral rivaroxaban affect the length of initial hospitalisation in patients with symptomatic DVT or PE?
Observational
Does oral rivaroxaban affect the length of initial hospitalisation in patients with symptomatic DVT or PE?
A study assessed the length of initial hospitalisation in patients with symptomatic DVT or PE treated with rivaroxaban in the EINSTEIN trials.
Provides no data on rivaroxaban's effect on hospital stay in DVT/PE; leaves open implications for early discharge protocols.
The phase III EINSTEIN deep vein thrombosis (DVT) and EINSTEIN pulmonary embolism (PE) trials demonstrated the potential of oral rivaroxaban (Xarelto, Bayer) -15 mg twice daily for 21 days, followed by 20 mg once daily -for the treatment of venous thromboembolism (VTE), a term that embraces DVT and PE. A subsequent study by van Bellen et al., [1] published in Current Medical Research and Opinion in 2014, was undertaken to assess the length of initial hospitalisation in patients presenting with either symptomatic DVT or PE using hospitalisation records from these trials.
No takes yet. Share an insight, caveat, or question.
Simon Nye (2016) conducted an observational in symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE). oral rivaroxaban was evaluated on length of initial hospitalisation. An analysis of the EINSTEIN trials assessed the length of initial hospitalisation for patients with DVT or PE treated with rivaroxaban, though no quantitative results were reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: